Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 288 for “"Temozolomide"”.
-
Circadian Regulation of Temozolomide Sensitivity in Glioblastoma
… by testing the efficacy of the DNA alkylator Temozolomide (TMZ) on GBM in vitro and in vivo as a function of time of day. We found cell-intrinsic, daily rhythms in susceptibility of GBM tumor cells (mouse astrocytes deficient in NF1 and p53 signaling) to TMZ in vitro. The greatest TMZ-induced …
-
Investigating acquired temozolomide resistance in adult glioblastoma
… management includes surgery, radiotherapy and temozolomide (TMZ), which causes three types of DNA methylation: O6-methylguanine (O<sup>6</sup>-meG), N7-methylguanine and N3-methyladenine. N-methylated lesions are mostly recognised and repaired by base excision repair (BER), while the most toxic …
-
Safety and effectiveness of extended temozolomide in glioblastoma patients
… by chemoradiation and six cycles of adjuvant temozolomide. The benefit of extending temozolomide beyond six cycles remains controversial. We investigated the effect of extended temozolomide on time to death. METHODS: A population-based retrospective cohort study was conducted using …
-
DLL4 and JAG1 in the Glioblastoma Response to Temozolomide Chemotherapy
… of surgery followed by radiotherapy and adjuvant temozolomide (TMZ) chemotherapy. Prognosis is poor, with a median survival of 14.6 months following diagnosis. Treatment often fails due to intrinsic or acquired TMZ resistance of a small population of cells termed glioma cancer stem cells (GCSCs). …
-
Temozolomide and Bevacizumab Therapy In Advanced Hemangiopericytoma/ Solitary Fibrous Tumor
… 14 patients with advanced HPC/SFT who received temozolomide and bevacizumab systemic therapy, the overall RECIST response rate was 14%, with the overall Choi response rate of 79%. The median PFS for the cohort was 9.7 months with a median 6-month progression free rate of 78.6%. The most …
-
Overcoming toxicity and resistance limitations of the anticancer drug temozolomide
Submission published under a 24 month embargo labeled 'Closed Access', the embargo will last until 2026-12-01
-
Preventing the Emergence of Temozolomide Resistance in Glioblastoma by PARP Inhibition
Temozolomide (TMZ) is active against the subset of glioblastomas (GBMs) in which the O6-methylguanine DNA-methyltransferase (MGMT) gene is silenced by promoter methylation. Unfortunately, virtually all MGMT-methylated tumors acquire TMZ resistance and regrow in patients. In a preliminary study, we …
-
Metabolomic Studies of Temozolomide Response in Patient-Derived Models of Glioblastoma
… is an aggressive primary brain tumour for which temozolomide (TMZ) remains a core component of first-line therapy as the only systemic drug with an established survival benefit in this setting. However, over half of patients exhibit intrinsic or acquired resistance and clinical tools remain …
-
Single-nucleotide-resolution genomic maps of temozolomide-induced DNA adducts in glioblastoma
Temozolomide (TMZ) is widely used for glioblastoma (GBM) therapy and functions by inducing DNA alkylation. Tumor cell killing is driven by repair pathways that eventually lead to apoptosis in fast replicating cells. While the combination of TMZ and radiother-apy improves overall survival by …
-
Tetra-o-methyl nordihydroguaiaretic acid and Temozolomide work synergistically on Glioblastoma Multiforme tumors
… poorly to the current treatment methods, temozolomide (TMZ) and radiation. Tetra-O-methyl-nordihydroguaiaretic acid (M4N), a global transcription repressor of genes, is potent when used on GBM cell lines. Here, we investigate the effects of M4N in combination with TMZ on GBM cell lines. …
-
Temozolomide-Induced Mismatch Repair Deficiency Accelerates Tumor Growth and Induces Radiosensitivity in Gliomas
… is represented by surgery, radiation therapy and temozolomide. The effectiveness of temozolomide depends on two pre-requisites. First, it requires a dysfunctional O6-methylguanine DNA methyltransferase (MGMT)-mediated DNA repair, which would otherwise directly reverse temozolomide-induced …
-
Subcellular proteomics of temozolomide-resistant glioblastoma multiforme cells by liquid chromatography/mass spectrometry
… poor overall survival time of about 15 months. Temozolomide (TMZ) is the first choice of chemotherapeutic drug to treat such tumors. The main challenge remains resistance development against TMZ. Resistance causes the treatment to fail in more than 50% of the patient population. Several efforts …
-
Targeting rhabdomyosarcoma with temozolomide: how autophagy regulates TMZ-induced apoptosis in rhabdomyosarcoma cells
… Treatment of RMS with the oral alkylating agent temozolomide (TMZ), alone or in combination with other drugs, has recently received considerable interest. However, the mechanism of action of TMZ remains unclear. The aim of this investigation was to determine if autophagy modulates TMZ-induced …
-
Multifunctional Liposomal Carriers Encapsulating Temozolomide, RG7388 and Elacridar for Targeted Glioblastoma Multiforme Therapy
… and efflux through the simultaneous delivery of temozolomide, RG7388 and elacridar in a single nano-carrier system. Two liposomal systems were characterized including a multilamellar system and nanoparticles in liposome system (PLL) were designed for this purpose.|The liposomes were surface …
Page 1 of 15